Tag: Phase 3 TROPiCS-02 study
What to Expect at ESMO 2022: Sacituzumab Govitecan Show PFS Benefits...
New data from a post hoc subgroup analysis from the Phase 3 TROPiCS-02 study evaluating sacituzumab govitecan-hziy* (Trodelvy®, Gilead Sciences) versus comparator chemotherapies (physicians’...